MORPHIC REPORTS NEW DATA FROM POSITIVE PHASE 1 STUDY OF MORF-057, ORAL INTEGRIN INHIBITOR CANDIDATE FOR IBD
  • About Us
      • Back
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
  • Technology
      • Back
      • Integrin Biology
      • The Journey to Oral Integrins
      • MInT Platform and Strategy
  • Pipeline
  • Investors
      • Back
      • Overview
      • Press Releases
      • Events
      • Stock Information
      • Corporate Governance
      • SEC Filings
  • Careers
  • Contact Us
 

  • For Integrin Medicines